TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

NCT06232759 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab

Sponsor

Guangxi Medical University